FPR2 and lung carcinoma: However, as an FPR2 agonist, WKYMVm stimulates FPR2 on the surface of CaLu-6 lung cancer cells, induces NADPH-dependent radical oxygen species (ROS) generation and c-Src activation, promotes epidermal growth factor receptor (EGFR) tyrosine phosphorylation, and transactivation of EGFR, further triggers the STAT3 pathway, thereby promoting lung cancer cell proliferation (Cattaneo et al., 2011) (Figure 2).